Intrathecal clonidine for refractory detrusor hyperreflexia in spinal cord injured patients: a preliminary report

J Urol. 1998 Dec;160(6 Pt 1):2137-8. doi: 10.1097/00005392-199812010-00050.

Abstract

Purpose: We assessed the urodynamic effect of various doses of intrathecal clonidine on refractory detrusor hyperreflexia in spinal cord injured patients.

Materials and methods: Doses of 15, 30 or 45 microg. intrathecal clonidine or placebo were given to 5 chronic complete spinal cord injured patients with detrusor hyperreflexia. Two cystometries were performed before and 5, 30, 60, 90, 120 and 180 minutes after each injection.

Results: A statistically significant dose dependent decrease in detrusor hyperreflexia was observed in each patient without significant side effect.

Conclusions: Intrathecal clonidine may represent a conservative reversible treatment for detrusor hyperreflexia via a subcutaneous programmable pump, like that used for baclofen, for spasticity. The long-term efficacy needs to be evaluated.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Agonists / pharmacology
  • Adrenergic alpha-Agonists / therapeutic use*
  • Clonidine / pharmacology
  • Clonidine / therapeutic use*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Injections, Spinal
  • Male
  • Reflex, Abnormal / drug effects*
  • Spinal Cord Injuries / complications
  • Spinal Cord Injuries / physiopathology*
  • Urinary Bladder Diseases / drug therapy*
  • Urinary Bladder Diseases / etiology
  • Urinary Bladder Diseases / physiopathology*
  • Urodynamics / drug effects*

Substances

  • Adrenergic alpha-Agonists
  • Clonidine